Atika Capital Management LLC Has $17.32 Million Position in Glaukos Corporation $GKOS

Atika Capital Management LLC trimmed its position in Glaukos Corporation (NYSE:GKOS) by 33.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,400 shares of the medical instruments supplier’s stock after selling 107,100 shares during the period. Glaukos makes up approximately 1.4% of Atika Capital Management LLC’s holdings, making the stock its 25th biggest holding. Atika Capital Management LLC owned 0.37% of Glaukos worth $17,321,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Primecap Management Co. CA increased its stake in Glaukos by 23.3% in the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock valued at $183,796,000 after purchasing an additional 425,790 shares in the last quarter. State Street Corp grew its holdings in shares of Glaukos by 5.3% in the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after buying an additional 105,972 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after buying an additional 68,497 shares during the period. Geode Capital Management LLC raised its stake in Glaukos by 9.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier’s stock worth $137,454,000 after buying an additional 115,529 shares during the period. Finally, Westfield Capital Management Co. LP lifted its holdings in Glaukos by 5.5% during the third quarter. Westfield Capital Management Co. LP now owns 1,231,641 shares of the medical instruments supplier’s stock worth $100,440,000 after acquiring an additional 63,788 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks published a bullish longer‑term view, initiating/issuing an FY2028 EPS forecast of $1.68, implying significant improvement versus the multi‑year loss trajectory and signaling potential upside if execution stays on track. MarketBeat: Zacks FY2028 estimate
• Neutral Sentiment: Zacks provided a full schedule of revised quarterly and annual estimates (Q1–Q4 2026, FY2026, Q1–Q4 2027, FY2027), which gives a clearer multi‑year earnings path but increases model dispersion versus the consensus (consensus full‑year EPS still shown at -$1.08). That creates both clarity and uncertainty for investors projecting valuation. MarketBeat: Zacks full estimate set
• Negative Sentiment: Zacks materially lowered near‑term estimates: Q1–Q4 2026 and several 2027 quarters were cut (examples: Q1 2026 to -$0.27 from -$0.16; Q2 2026 to -$0.24 from -$0.12; Q3 2026 to -$0.15 from -$0.05; Q4 2026 to -$0.01 from $0.04; Q1 2027 to -$0.10 from $0.01; Q2–Q3 2027 also down). Zacks reduced FY2026 to -$0.67 (from -$0.29) and cut FY2027 to $0.42 (from $0.78). Those downgrades push expected profitability further out and are the main driver of today’s share weakness. MarketBeat: Zacks cuts to near‑term EPS

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the sale, the director directly owned 37,449 shares of the company’s stock, valued at $4,782,611.79. The trade was a 28.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Joseph E. Gilliam sold 10,498 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the transaction, the chief operating officer owned 92,366 shares of the company’s stock, valued at approximately $11,793,290.88. This represents a 10.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 320,000 shares of company stock valued at $37,202,909. Corporate insiders own 5.80% of the company’s stock.

Glaukos Stock Down 0.2%

Shares of Glaukos stock opened at $102.91 on Thursday. The business’s 50 day simple moving average is $115.21 and its 200 day simple moving average is $101.19. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $130.23. The firm has a market cap of $5.98 billion, a PE ratio of -31.57 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company’s revenue was up 35.6% compared to the same quarter last year. During the same period last year, the company earned ($0.40) EPS. On average, analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GKOS. Piper Sandler restated an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. UBS Group boosted their price objective on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Citigroup upped their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Needham & Company LLC raised their price objective on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.